# A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults

> **NCT04380701** · PHASE1,PHASE2 · COMPLETED · sponsor: **BioNTech SE** · enrollment: 512 (actual)

## Conditions studied

- Infections, Respiratory
- Virus Diseases
- Infection Viral
- Vaccine Adverse Reaction
- RNA Virus Infections
- Protection Against COVID-19 and Infections With SARS CoV 2

## Interventions

- **BIOLOGICAL:** BNT162a1
- **BIOLOGICAL:** BNT162b1
- **BIOLOGICAL:** BNT162b2
- **BIOLOGICAL:** BNT162c2

## Key facts

- **NCT ID:** NCT04380701
- **Lead sponsor:** BioNTech SE
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-23
- **Primary completion:** 2021-06-30
- **Final completion:** 2022-04-13
- **Target enrollment:** 512 (ACTUAL)
- **Last updated:** 2024-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04380701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04380701, "A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04380701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*